Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study.
Adv TherJul 24, 2026 (epub)
Emilie R Elliot, Justine Boles, Dainielle Fox et al.
✦ AI-curated · Sources linked
In 30 seconds
The CLARITY study, a randomized crossover trial involving adults without HIV, compared the acceptability of long-acting cabotegravir (CAB LA) and lenacapavir (LEN LA) injections. Results showed that 69% of participants found CAB LA injections 'totally or very acceptable' compared to 48% for LEN LA (odds ratio, 3.4; P < 0.019).
Key findings
- 69% of participants rated CAB LA as 'totally or very acceptable' compared to 48% for LEN LA.
- CAB LA had fewer visible injection site reactions (36 vs. 221) than LEN LA.
- 90% of participants preferred CAB LA over LEN LA.
- 86% of healthcare providers preferred CAB LA.
Why it matters
Understanding patient and provider preferences for long-acting injectables is crucial for shared decision-making. The findings suggest that CAB LA may enhance patient satisfaction and adherence due to its favorable acceptability and lower incidence of injection site reactions.